A Rare Cause of Postoperative Bleeding from A Lytic Lesion of Calcaneum (original) (raw)
Related papers
American Journal of Clinical Oncology, 2014
BACKGROUND-Angiosarcoma of bone is a rare high-grade malignant vascular tumor. The literature regarding treatment and outcome of patients with this tumor is limited. We performed a two-institutional retrospective study to analyze treatment and survival of patients with angiosarcoma of bone. PATIENTS AND METHODS-We reviewed patients with the histological diagnosis of primary angiosarcoma of bone treated from 1980 to 2009. Demographic details, histology, treatment and survival were reviewed. RESULTS-38 men, 22 women (median age 54 years). Most lesions occurred in the femur and the pelvis. Metastatic disease at presentation was diagnosed in 24 patients (40%). Forty-three patients underwent surgery, with 30 of them achieving surgical complete remission (SCR). Radiotherapy (RT) was applied to 17 patients, and chemotherapy (CT) to 13/35 and 15/22 patients with localized and metastatic disease, respectively. The 5-year overall survival (OS) was 20%: 33% for patients with localized disease and 0% for metastatic patients. Higher 5-year OS was reported for patients who achieved SCR (46%) than for
2020
Background Angiosarcoma is a rare malignant tumor, originating from vascular endothelial cells, accounting for approximatively 1–2% of soft tissue sarcomas. It is characterized by a rapid proliferation and high metastatic potential. Some cases of angiosarcoma are described in association with vascular prosthesis, orthopedic devices and foreign bodies. Hereby, we report a case of a patient treated with the endovascular placement of a PTFE aorto bis-iliac prosthesis for aortic aneurysm, who developed a graft-related angiosarcoma with bone and peritoneal localizations. The peritoneal “sarcomatosis” led to an acute presentation with hemoperitoneum and anemia. We perform a thorough review of the literature summarizing the description of similar cases, their epidemiology and the possibilities for treatment. Case presentation An 84-year-old male with a history of abdominal aortic aneurysm endovascular repair presented to our emergency department complaining with low back pain radiating to ...
International Seminars in Surgical Oncology, 2008
Angiosarcoma of bone is an exceedingly rare primary bone malignancy that can present as an aggressive osteolytic lesion. Histological diagnosis can be extremely challenging, as the pathological features often resemble that of aneurysmal bone cysts. We report an interesting and peculiar case of an intraosseous angiosarcoma that presented as a diagnostic dilemma and discuss the relevant radiological and pathologic findings.
Angiosarcoma of bone: a retrospective study of the European Musculoskeletal Oncology Society (EMSOS)
Scientific Reports
Angiosarcoma of bone (B-AS) is a rare malignant tumor of vascular origin. the aim of this retrospective study is to report on treatments and prognosis. Data were collected from the EMSOS website. 80 patients in 9 centers included: 51 male/29 female; median age 54 years (range 17 to 92); 56% with localized disease, 44% metastatic. Primary tumor surgery: 76% (30% amputation, 26% intralesional margins); radiotherapy (RT): 41%; chemotherapy (CT): 47% (56% in metastatic, 41% in localized cases). With a median follow-up of 31 months (range 40 to 309), 5-year overall survival (OS) was 27% (95%CI 16-30): 41% (95%CI 25-56) for localized patients, and 8% (95%CI 0-20) for metastatic (p = 0.002). In metastatic patients, 1 year OS was significantly influenced by chemotherapy response: 67% (95CI% 29-100) for those who responded or had stable disease (n = 7), and 18% (95CI% 0-41) for patients with progressive disease (n = 11), p 0.002. The surgical complete remission (SCR) status was pivotal in localized patients (5-year OS 45% for SCR, 17% no SCR, p = 0.03); also 5-year OS was significantly influenced by age and site of the tumor. After multivariate analysis, the addition of radiotherapy to surgery significantly influenced the disease-free survival (DFS) rate, whereas the use of chemotherapy lost the significance showed at the univariate analysis. Overall, patients with metastatic B-AS have a dismal prognosis, with a prolonged survival in case with a response to chemotherapy. experimental trials with more active systemic treatment regimens are needed. in patients with localized disease, the patient's age and site of the tumor are prognostic factors and any effort must be made to achieve an SCR status. No definitive conclusions can be drawn from our data on the use of adjuvant chemotherapy, while the use of adjuvant radiotherapy might improve DSf in patients surgically free of disease. Angiosarcoma of bone (B-AS) is exceedingly rare, accounting for less than 1% of all primary bone sarcomas, with the highest incidence between 50 and 70 years of age 1,4. The diagnosis of B-AS is challenging and represents the malignant end of the spectrum of CD31/ERG positive vascular tumors, including hemangiomas, hemangioendotheliomas, well-differentiated and poorly differentiated angiosarcomas 1-3 (Fig. 1). The disease might present as unifocal or with multifocal bone lesions, and it is usually associated with a poor prognosis 1-6. Given the rarity of B-AS, only scant information can be found in the literature, mostly reported in form of small series and case reports. No specific treatment guidelines or position papers are available, so the treatment of choice is based on data from other types of bone and soft tissue sarcomas 1,3-7. The role of chemotherapy and prognostic factors for
Distinct histological features characterize primary angiosarcoma of bone
Histopathology, 2011
Aims: To define the histological criteria of primary angiosarcoma of bone. Methods and results: Forty-two angiosarcomas of bone in 23 males and 15 females were studied. Histological criteria were related to patients' outcome. Eleven patients had multifocal lesions. Lesions were located in the long and short tubular bones followed by the pelvis, spine and trunk. Tumour cells were positive for CD31 in 38 of 40, von Willebrand Factor in 21 of 35, CD34 in 15 of 38, smooth muscle actin in 22 of 36, D2-40 in 11 of 35 and keratinAE1AE3 in 27 of 39. Thirty-nine tumours showed an epithelioid phenotype.
Odisha Journal of Orthopaedics and Trauma
Background: Osteoblastoma is a rare bone forming neoplasm and it is very rare to present with secondary cystic changes that too in the heel bone. The incidence is <0.6 % among all and its prevalence is yet to be reported in our population. owing to its rare presentation the early diagnosis of Osteoblastoma of calcaneum with secondary aneurysmal cyst like changes are difficult and hence affects the outcome. Material: In this report we detailed the diagnostic methods and surgical management of osteoblastoma of calcaneum associated with secondary aneurysmal cyst like changes in a 12year old boy with 2 year follow up. Result: It shown that the expansile lytic lesion was healed at appropriate time period and ankle & subtalar range of movements were satisfactory with no limitation in inversion and eversion. Conclusion: Benign expansile bone tumors in heel bone are difficult to find in the literature. This study addresses the diagnostic modality, proper surgical management in terms of a...
Human Pathology, 1971
Primary tumors of bone of vascular origin are rare. Consequently, knowledge of their clinical and pathologic features is still scant)'. A morass of ntisleading terminolog-y, particularly in connection with the malignant vascular tumors, has added to the difficulties. Tiffs paper is a review of our current knowledge of these lesions based on a series of 42 personally studied cases. It presents a classification of the vascular ttmtors of bone and its coverings and attempts to sort out in an orderly way tim confusing array of terms applied to the ntalignant bone tumors of blood vessel origin.